An investigation on behalf of investors in NASDAQ:TRV shares was announced concerning possible violations of securities laws by Trevena Inc in connection certain financial statements.
Investors who purchased shares of Trevena Inc (NASDAQ:TRVN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statements by Trevena Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
King of Prussia, PA based Trevena Inc. is a clinical-stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use an approach to target G protein coupled receptors.
February 21, 2017, Trevena Inc announced the clinical trial results for its morphine-alternative drug, Oliceridine, which revealed that the drug did not have statistically significant rates of higher tolerability or safety as compared to standard morphine.
Shares of Trevena Inc (NASDAQ:TRVN) closed on March 24, 2017 at $3.55 per share.
Those who purchased NASDAQ:TRVN shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com